sorafenib has been researched along with aspirin in 12 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (aspirin) | Trials (aspirin) | Recent Studies (post-2010) (aspirin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 48,947 | 6,817 | 13,778 |
| Protein | Taxonomy | sorafenib (IC50) | aspirin (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.35 | |
| Integrin beta-3 | Homo sapiens (human) | 5 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.8252 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 1.375 | |
| Integrin alpha-IIb | Homo sapiens (human) | 5 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.271 | |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | 2.4 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 2.15 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 0.3 | |
| 4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 2.4 | |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.35 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4081 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baek, YH; Cho, JH; Han, JS; Han, SY; Kim, BG; Kim, SO; Lee, SW; Nam, KJ | 1 |
| Boersma-van Ek, W; de Jong, S; de Vries, EG; Hollema, H; Kleibeuker, JH; Kruyt, FA; Pennarun, B | 1 |
| Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD | 1 |
| Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W | 1 |
| Gao, M; Hua, H; Jiang, Y; Kong, Q; Luo, T; Wang, J; Yin, Y | 1 |
| Jang, H; Kim, EH; Roh, JL; Shin, D | 1 |
| Dai, X; Ding, J; Fu, X; Geng, M; Huang, M; Huang, X; Liu, H; Shen, A; Sun, D; Wei, R; Yan, J; Zheng, X | 1 |
| Chen, K; Dai, W; Fan, X; Feng, J; Guo, C; Li, J; Li, S; Liu, T; Lu, J; Lu, X; Mo, W; Wang, W; Wu, L; Xia, Y; Xu, L; Xu, S; Yu, Q; Zhang, Q; Zhou, Y | 1 |
| Manoharan, R; Natarajan, SR; Ponnusamy, L; Thangaraj, K | 1 |
| Astara, G; Bernardini, L; Casadei-Gardini, A; Cascinu, S; D'Amico, FE; Dadduzio, V; Fornaro, L; Lai, E; Lonardi, S; Masi, G; Pretta, A; Rimini, M; Rovesti, G; Scartozzi, M; Vivaldi, C; Zagonel, V | 1 |
2 review(s) available for sorafenib and aspirin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Aspirin; Biological Products; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Activators; Female; Humans; Metformin; Phosphorylation; Signal Transduction; Sorafenib; Treatment Outcome | 2020 |
10 other study(ies) available for sorafenib and aspirin
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
Topics: Aged; Antineoplastic Agents; Aspirin; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Spleen; Splenic Infarction; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoma; Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Therapy, Combination; Gene Knockdown Techniques; Humans; Intestinal Mucosa; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Stem Cell Assay | 2013 |
Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
Topics: Acetyltransferases; Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
Topics: Animals; Aspirin; Benzylamines; Carcinoma, Hepatocellular; Cell Proliferation; Chemokine CXCL12; Cyclams; Down-Regulation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; Sorafenib; Tumor Microenvironment | 2015 |
AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Topics: Amino Acid Transport System y+; Animals; Antioxidants; Apoptosis; Aspirin; Cell Line, Tumor; Cisplatin; DNA Damage; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glutathione; Head and Neck Neoplasms; Humans; Mice; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Drug Therapy, Combination; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Regulatory-Associated Protein of mTOR; Sorafenib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphofructokinase-2; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib.
Topics: Antineoplastic Agents; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |